A Literature Review on Future Perspective of Metformin use for Chemotherapy

Authors

  • Teklu Gebrehiwot Gebremichael
  • Hagos Abreha (MD)
  • Hiluf Hindeya
  • Geush Meressa

Abstract

The emergence of metformin as a potential anticancer and cancer-preventive therapeutic tool is exciting. More recently, metformin has been associated with decreased cancer incidence and mortality in diabetic patients and the insulin-lowering effects of metformin are integral to its anticancer properties. With the added benefits of being readily available, economical, and easily tolerated with good safety profile, it can be effortlessly transitioned from bench to bedside for cancer therapy. So, this review focuses on the clinical future perspectives of metformin for its anti-cancer therapy according to a search engine on PubMed, Cochrane library and google scholar mainly for laboratory studies, case-control, observational, cohort and clinical trial studies. Based on the available data a depth review was done on 43 articles and scholar opinions. Available data suggest that metformin have potential applications for adjuvant, palliative treatment and prevention of cancer. Importantly, metformin use has been associated with a significant decrease in the relative risk of specific cancers, such as prostate, pancreas and breast cancers.

 

Keywords: Metformin, Chemotherapy, Cancer, Diabetes

 

Cite this Article

Teklu Gebrehiwot Gebremichael, Hagos Abreha (MD), Hiluf Hindeya, Geush Meressa. A Literature Review on Future Perspective of Metformin use for Chemotherapy. Research & Reviews: Journal of Oncology and Hematology. 2020; 9(3): 1–9p.

Downloads

Published

2021-01-13

Issue

Vol. 9 No. 3 (2020)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.